Oral Transmucosal Drugs May Prevent Rapid Deterioration of COVID-19 Patients

The COVID-19 pandemic has led to a need for alternative routes of drug administration for end of life and palliative care. This has brought stakeholders in the oral transmucosal drugs market under scrutiny, especially in community settings. Popular transmucosal routes such as buccal, intranasal, sublingual, and rectal are being publicized. This has led to the scope of non-invasive routes for systematic drug delivery with the potential for self-administration or administration by family caregivers.

Companies in the oral transmucosal drugs market are capitalizing on the ability to offer rapid onset of action with reduced first-pass metabolism. Oral transmucosal drugs are being increasingly used in palliative and end of life care to provide fast relief of symptoms. Such findings are benefitting healthcare providers during the coronavirus outbreak, since the health of some patients tends to deteriorate rapidly in certain cases.

oral transmucosal drugs market infographic

To know the scope of our report Get a Sample on Oral Transmucosal Drugs Market

Mucoadhesive Polymers Hold High Potential to Improve Drug Delivery in Patients

The successful delivery of drugs across the oral mucosa represents a continuing challenge as well as an opportunity for stakeholders in the oral transmucosal drugs market. This explains why the market is estimated to clock a favorable CAGR of ~6% during the forecast period. Hence, companies are expected to collaborate with researchers, scientists, and biologists to increase R&D in novel mucoadhesive polymers. They are increasing efforts to design improved drug delivery systems that achieve delivery through the different mucosa.

Transmucosal drug delivery systems are gaining increased popularity, as mucous membranes are relatively permeable, which facilitate the rapid uptake of a drug into the systemic circulation. Companies are boosting their production capabilities in mucoadhesive polymers under different dosage forms such as tablets, films, semisolids, and powders.

Get a glimpse of the in-depth analysis through our Report Brochure

Novel Permeation Enhancers Enable Active Ingredients to Penetrate Mucosa

Despite the number of advantages linked with transmucosal drug delivery, the medicines delivered as buccal or sublingual formulations remain relatively low. Aquestive Therapeutics - a specialty pharmaceutical company is finding opportunity in this challenge, and increasing its focus on developing novel permeation enhancers, stabilizers, and polymer blends that can boost the ability of active ingredients to penetrate the mucosa. Such innovations explain why the oral transmucosal drugs market is expected to reach US$ 27 Bn by 2031.

Proprietary compositional profiles of oral films are being tailored to the buccal or sublingual microenvironment in order to achieve a desired rate of absorption. This is evident since buccal films are likely to dominate the second-highest revenue among all drug types in the oral transmucosal drugs market.

Buccal Films Preferred Over Buccal Tablets

Extensive research is being carried out on the design and development of innovative drug delivery systems to improve their efficacy, safety, and patient compliance. Buccal films are the most recently developed dosage form for buccal administration. Companies in the oral transmucosal drugs market are capitalizing on this opportunity, since buccal films are gaining importance as efficacious and novel drug delivery systems that are cost-efficient and enable good patient compliance.

As buccal films are implied for attachment to the buccal mucosa, they can be formulated to exhibit local as well as systemic action. Pharmaceutical companies in the oral transmucosal drugs market are bolstering their output capacities in buccal films, since they are being preferred over buccal tablets, owing to the former’s flexibility and comfort. It has been found that buccal films have direct access to the systemic circulation through the jugular vein, which bypasses the drug from the hepatic first pass metabolism leading to the high bioavailability.

Precision Dosing Capacities of Oral Thin Films Grabbing Attention of Stakeholders

Oral thin films are storming the oral transmucosal drugs market. CURE Pharmaceutical Holding Corp. is gaining popularity for its flagship technology CUREfilm® that is a thin oral film platform, which optimizes the absorption and metabolism of therapeutic actives. Companies are taking cues from such innovations, and focusing on the oral soluble film technology that offers a versatile dose form and allows manufacturers to create proprietary products with optimal release profiles. This ensures better patient outcomes with oral thin films and enhanced consumer experiences.

Companies in the oral transmucosal drugs market are increasing their production of oral thin films, attributed to ease of use, high load, precision dosing, and fast acting capacities.

Mucoadhesion Helps Prolong Residence Time of Drugs on Mucus

The advanced materials for drug delivery across mucosal barriers are being developed by companies in the oral transmucosal drugs market. Mucus is a viscoelastic gel that traps pathogens and other foreign particles to limit their penetration into the underlying epithelium. On the other hand, dosage forms containing particle-based drug delivery systems are trapped in mucosal layers and tend to be removed by mucus turnover. This has driven companies in the oral transmucosal drugs market to increase their R&D activities in mucoadhesion, which helps to avoid premature wash-off and prolongs the residence time of drugs on mucus.

Mucoadhesion helps in mucus penetration, which is essential for molecules to access the underlying epithelial tissues. As such, various strategies are being investigated to achieve mucoadhesion and mucus penetration of drug carriers.

Micro, Nanoscale Drug Carriers Enable Sustainable Release of Drugs at Target Sites

The pharmaceutical companies in the oral transmucosal drugs market are acquiring a strong research base in micro and nanoscale technologies. The smart and controlled oral drug deliveries are predicted to bypass the physiological barriers that limit the oral delivery of hydrophilic therapeutics. Micro and nanoscale technologies are known for their unprecedented ability to create, control, and measure micro- or nano-environments that have found increased number of applications in biology and medicine.

Micro and nanoscale drug carriers such as bioadhesives, microparticles and nano-particles are being developed by pharmaceutical companies. The integration of bioadhesive properties improves the oral drug delivery of fabricated carriers. One of the key purpose of utilizing bio-adhesive materials is to delay the transit of cargos to enable the sustainable release of drugs at target sites. This helps to prolong the residence time in order to enhance the drug absorption process.

oral transmucosal drugs market segmentation

Expanding operations in future? To get the perfect launch ask for a custom report

Analysts’ Viewpoint

Though oral transmucosal drugs have the potential for self-administration in COVID-19 patients, it is met with challenges such as relatively small surface area for effective drug absorption. Companies are increasing their R&D activities to better the drug administration in coronavirus patients, since even after vaccination there is a high risk of reinfection in patients.

The oral administration is one of the most important pillars of the pharmaceutical industry. However, it is still challenging to administer hydrophilic therapeutics by the oral route. Hence, companies in the oral transmucosal drugs market should mainly focus on the design of carriers with bio-adhesive properties for oral transmucosal drugs and the administration of hydrophilic therapeutics.

Oral Transmucosal Drugs Market: Overview

  • This report analyzes the current scenario and future prospects of the global oral transmucosal drugs market. Rise in adoption of oral transmucosal drugs among the geriatric population and surge in prevalence of dysphagia are the key factors projected to drive the global oral transmucosal drugs market during the forecast period.
  • The report includes an elaborate executive summary, which provides a snapshot of various segments of the global oral transmucosal drugs market. It also provides information and data analysis of the oral transmucosal drugs market about segments based on type, route of penetration, distribution channel, indication, and region.
  • The overview section of the report provides a detailed qualitative analysis of drivers, restraints, and opportunities that impact the global oral transmucosal drugs market
  • The report includes company profiles, which provide information about their business, product portfolios, and competitive landscape in the global oral transmucosal drugs market
  • The report on the oral transmucosal drugs market offers market attractiveness analysis of regions and segments
  • The last section of the report comprises quantitative and qualitative analyses on market share/position of key players operating in the global oral transmucosal drugs market. It analyzes key competitive strategies adopted by major industry players, thereby presenting a thorough understanding of the competitive scenario in the global oral transmucosal drugs market.

Oral Transmucosal Drugs market: Key Segments

  • In terms of type, the global oral transmucosal drugs market has been classified into tablets, buccal films, liquid & spray, gels, and others. The tablets segment dominated the global market in 2020, owing to the advantages offered by oral transmucosal tablets. These include improved stability, cost-effectiveness, rapid dissolution and absorption of drug, low sensitivity to environmental condition, and ease of administration.
  • The tablets segment has been split into sublingual tablets, buccal tablets, lozenges & troches, and others
  • Based on route of penetration, the global oral transmucosal drugs market has been categorized into sublingual mucosa, buccal mucosa, gingival tissues, and palatal tissues. The buccal mucosa segment dominated the global market in 2020.
  • In terms of distribution channel, the global oral transmucosal drugs market has been divided into hospital pharmacies, retail pharmacies, and online pharmacies. The online pharmacies segment is expected to expand at a high CAGR from 2021 to 2031. Detailed product information available on the site and rise in convenience in choosing drug from websites are likely to augment the segment.
  • Based on indication, the global oral transmucosal drugs market has been divided into cardiovascular disorders, acute pain management, sedation, erectile dysfunction, diabetes, and others. The diabetes segment is projected to expand at a high CAGR from 2021 to 2031, owing to rise in prevalence of diabetes worldwide.
  • Market size and forecast for each of these segments have been provided from 2017 to 2031. The CAGR of respective segment has also been provided from 2021 to 2031, considering 2020 as the base year.

Oral Transmucosal Drugs Market: Regional Outlook

  • In terms of region, the global oral transmucosal drugs market has been segmented into North America (the U.S. and Canada), Europe (the U.K., Germany, Spain, Italy, France, and Rest of Europe), Asia Pacific (China, India, Japan, Australia & New Zealand, South Korea, and Rest of Asia Pacific), Latin America (Brazil, Mexico, and Rest of Latin America), and Middle East & Africa (GCC Countries, South Africa, and Rest of Middle East & Africa). Each region considered in the market has been divided into countries/sub-regions.
  • The oral transmucosal drugs market report provides size and forecast for each region and country/sub-region from 2017 to 2031. The CAGR for each of these regions and countries has also been provided for the forecast period from 2021 to 2031. The oral transmucosal drugs market study also covers the competitive scenario in these regions.

Companies Covered in Oral Transmucosal Drugs Market Report

  • Key players in the global oral transmucosal drugs market have been profiled based on attributes such as company overview, product portfolio, financial overview, recent developments, and competitive business strategies
  • Major companies profiled in the oral transmucosal drugs market report are
    • LTS Lohmann Therapie-Systeme AG
    • Soligenix
    • ZIM Laboratories Limited
    • Access Pharmaceutical Inc.
    • C.L Pharm
    • Seoul Pharmaceuticals
    • Cure Pharmaceutical
    • Aquestive Therapeutics, Inc.
    • Solvay S.A.
    • NAL Pharma
    • IntelGenx Corp.
    • Izun Pharmaceuticals
    • Eisai Co., Ltd.
    • AstraZeneca
    • Otsuka Pharmaceutical Co., Ltd.
    • Pfizer, Inc.
    • Teva Pharmaceutical Industries Ltd.
    • GlaxoSmithKline plc
    • Mylan N.V.
    • Bristol-Myers Squibb Company

Oral Transmucosal Drugs Market – Scope of Report

TMR’s report on the global oral transmucosal drugs market studies past as well as current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2021 to 2031. The report provides revenue of the global oral transmucosal drugs market for the period of 2017–2031, considering 2020 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR) for the global oral transmucosal drugs market during the forecast period.

The report has been prepared after primary and secondary researches. Primary research involved bulk of research efforts, wherein analysts carried out interviews with industry leaders and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the global oral transmucosal drugs market.

Secondary research also included Internet sources, statistical data from government agencies, websites, company presentations, sales data, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various phenomenon in the global oral transmucosal drugs market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Furthermore, the report sheds light on the changing competitive dynamics in the global oral transmucosal drugs market. These indices serve as valuable tools for existing market players as well as for entities interested in entering the global oral transmucosal drugs market.

The report delves into the competitive landscape of the global oral transmucosal drugs market. Key players operating in the global oral transmucosal drugs market have been identified, and each one of these has been profiled for distinguishing business attributes. Company overview, financial standings, recent developments, and SWOT are some of the attributes of players in the global oral transmucosal drugs market that have been profiled in this report.

Key Questions Answered in Oral Transmucosal Drugs Market Report

  • What are the major drivers, restraints, and opportunities in the market?
  • What will be the Y-o-Y growth of the global oral transmucosal drugs market between 2021 and 2031?
  • What are the revenue share projections of key segments of the global oral transmucosal drugs market during the forecast period?
  • Will North America continue to be the most profitable market for oral transmucosal drugs?
  • Which factors are anticipated to restrain the global oral transmucosal drugs market during the forecast period?
  • Which are the leading companies in the global oral transmucosal drugs market?

Research Methodology

A unique methodology has been utilized by TMR to conduct comprehensive research on the growth of the global oral transmucosal drugs market and arrive at conclusions on its growth prospects. This research methodology is a combination of primary and secondary research, which helps analysts warrant the accuracy and reliability of the drawn conclusions.

Secondary research sources referred to by analysts during the production of the global oral transmucosal drugs market report include statistics from company annual reports, SEC filings, company websites, investor presentations, regulatory databases, government publications, and industry white papers. Analysts have also interviewed senior managers, product portfolio managers, CEOs, VPs, and market intelligence managers, who contributed to the production of TMR’s study on the oral transmucosal drugs market as primary methods.

These primary research respondents have provided exclusive information during interviews, which serves as a validation from the oral transmucosal drugs market leaders. Access to an extensive internal repository and external proprietary databases enabled this report to address specific details and questions about the global oral transmucosal drugs market with accuracy. The study also uses the top-down approach to assess the revenue of each segment and the bottom-up approach to counter-validate them. This has helped in reaching TMR’s estimates on future prospects of the global oral transmucosal drugs more reliably and accurately.

Oral Transmucosal Drugs Market – Segmentation

Type
  • Tablets
    • Sublingual Tablets
    • Buccal Tablets
    • Lozenges & Troches
    • Others
  • Buccal Films
  • Liquid & Spray
    • Aqueous Solutions
    • Suspensions
  • Gels
  • Others
Route of Penetration
  • Sublingual Mucosa
  • Buccal Mucosa
  • Gingival Tissues
  • Palatal Tissues
Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
Indication
  • Cardiovascular Disorders
  • Acute Pain Management
  • Sedation
  • Erectile Dysfunction
  • Diabetes
  • Others
Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

1. Preface

    1.1. Market Definition and Scope

    1.2. Market Segmentation

    1.3. Key Research Objectives

    1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Oral Transmucosal Drugs Market

4. Market Overview

    4.1. Introduction

        4.1.1. Type Definition

        4.1.2. Industry Evolution / Developments

    4.2. Overview

    4.3. Market Dynamics

        4.3.1. Drivers

        4.3.2. Restraints

        4.3.3. Opportunities

    4.4. Global Oral Transmucosal Drugs Market Analysis and Forecast, 2017–2031

5. Key Insights

    5.1. Key Mergers & Acquisitions 

    5.2. COVID-19 Pandemic Impact on Industry (value chain and short / mid / long term impact)

    5.3. Top 3 players operating in the market space

    5.4. Clinical Trials & Pipeline Analysis

    5.5. Oral Transmucosal Drugs Market SWOT Analysis

6. Global Oral Transmucosal Drugs Market Analysis and Forecast, by Type

    6.1. Introduction & Definition

    6.2. Key Findings / Developments

    6.3. Market Value Forecast, by Type, 2017–2031

        6.3.1. Tablets

            6.3.1.1. Sublingual Tablets 

            6.3.1.2. Buccal Tablets 

            6.3.1.3. Lozenges & Troches

            6.3.1.4. Others

        6.3.2. Buccal Films 

        6.3.3. Liquid & Spray

            6.3.3.1. Aqueous Solutions

            6.3.3.2. Suspensions 

        6.3.4. Gels

        6.3.5. Others

    6.4. Market Attractiveness Analysis, by Type 

7. Global Oral Transmucosal Drugs Market Analysis and Forecast, by Route of Penetration

    7.1. Introduction & Definition

    7.2. Key Findings / Developments

    7.3. Market Value Forecast, by Route of Penetration, 2017–2031

        7.3.1. Sublingual Mucosa

        7.3.2. Buccal Mucosa

        7.3.3. Gingival Tissues

        7.3.4. Palatal Tissues

    7.4. Market Attractiveness Analysis, by Route of Penetration 

8. Global Oral Transmucosal Drugs Market Analysis and Forecast, by Distribution Channel

    8.1. Introduction & Definition

    8.2. Key Findings / Developments

    8.3. Market Value Forecast, by Distribution Channel, 2017–2031

        8.3.1. Hospital Pharmacies

        8.3.2. Retail Pharmacies

        8.3.3. Online Pharmacies

    8.4. Market Attractiveness Analysis, by Distribution Channel 

9. Global Oral Transmucosal Drugs Market Analysis and Forecast, by Indication

    9.1. Introduction & Definition

    9.2. Key Findings / Developments

    9.3. Market Value Forecast, by Indication, 2017–2031

        9.3.1. Cardiovascular Disorders

        9.3.2. Acute Pain Management

        9.3.3. Sedation

        9.3.4. Erectile Dysfunction

        9.3.5. Diabetes

        9.3.6. Others

    9.4. Market Attractiveness Analysis, by Indication 

10. Global Oral Transmucosal Drugs Market Analysis and Forecast, by Region

    10.1. Key Findings

    10.2. Market Value Forecast, by Region

        10.2.1. North America 

        10.2.2. Europe 

        10.2.3. Asia Pacific 

        10.2.4. South Korea 

        10.2.5. Latin America 

        10.2.6. Middle East & Africa 

    10.3. Market Attractiveness Analysis, by Country/Region

11. North America Oral Transmucosal Drugs Market Analysis and Forecast

    11.1. Introduction

        11.1.1. Key Findings

    11.2. Market Value Forecast, by Type, 2017–2031

        11.2.1. Tablets

            11.2.1.1. Sublingual Tablets 

            11.2.1.2. Buccal Tablets 

            11.2.1.3. Lozenges & Troches

            11.2.1.4. Others

        11.2.2. Buccal Films 

        11.2.3. Liquid & Spray

            11.2.3.1. Aqueous Solutions

            11.2.3.2. Suspensions 

        11.2.4. Gels

        11.2.5. Others

    11.3. Market Value Forecast, by Route of Penetration, 2017–2031

        11.3.1. Sublingual Mucosa

        11.3.2. Buccal Mucosa

        11.3.3. Gingival Tissues

        11.3.4. Palatal Tissues

    11.4. Market Value Forecast, by Distribution Channel, 2017–2031

        11.4.1. Hospital Pharmacies

        11.4.2. Retail Pharmacies

        11.4.3. Online Pharmacies

    11.5. Market Value Forecast, by Indication, 2017–2031

        11.5.1. Cardiovascular Disorders

        11.5.2. Acute Pain Management

        11.5.3. Sedation

        11.5.4. Erectile Dysfunction

        11.5.5. Diabetes

        11.5.6. Others

    11.6. Market Value Forecast, by Country, 2017–2031

        11.6.1. U.S. 

        11.6.2. Canada 

    11.7. Market Attractiveness Analysis 

        11.7.1. By Type 

        11.7.2. By Route of Penetration 

        11.7.3. By Distribution Channel 

        11.7.4. By Indication 

        11.7.5. By Country

12. Europe Oral Transmucosal Drugs Market Analysis and Forecast

    12.1. Introduction

        12.1.1. Key Findings

    12.2. Market Value Forecast, by Type, 2017–2031

        12.2.1. Tablets

            12.2.1.1. Sublingual Tablets 

            12.2.1.2. Buccal Tablets 

            12.2.1.3. Lozenges & Troches

            12.2.1.4. Others

        12.2.2. Buccal Films 

        12.2.3. Liquid & Spray

            12.2.3.1. Aqueous Solutions

            12.2.3.2. Suspensions 

        12.2.4. Gels

        12.2.5. Others

    12.3. Market Value Forecast, by Route of Penetration, 2017–2031

        12.3.1. Sublingual Mucosa

        12.3.2. Buccal Mucosa

        12.3.3. Gingival Tissues

        12.3.4. Palatal Tissues

    12.4. Market Value Forecast, by Distribution Channel, 2017–2031

        12.4.1. Hospital Pharmacies

        12.4.2. Retail Pharmacies

        12.4.3. Online Pharmacies

    12.5. Market Value Forecast, by Indication, 2017–2031

        12.5.1. Cardiovascular Disorders

        12.5.2. Acute Pain Management

        12.5.3. Sedation

        12.5.4. Erectile Dysfunction

        12.5.5. Diabetes

        12.5.6. Others

    12.6. Market Value Forecast, by Country/Sub-region, 2017–2031

        12.6.1. Germany 

        12.6.2. U.K. 

        12.6.3. France 

        12.6.4. Italy 

        12.6.5. Spain 

        12.6.6. Rest of Europe 

    12.7. Market Attractiveness Analysis 

        12.7.1. By Type 

        12.7.2. By Route of Penetration 

        12.7.3. By Distribution Channel 

        12.7.4. By Indication 

        12.7.5. By Country/Sub-region

13. Asia Pacific Oral Transmucosal Drugs Market Analysis and Forecast

    13.1. Introduction

        13.1.1. Key Findings

    13.2. Market Value Forecast, by Type, 2017–2031

        13.2.1. Tablets

            13.2.1.1. Sublingual Tablets 

            13.2.1.2. Buccal Tablets 

            13.2.1.3. Lozenges & Troches

            13.2.1.4. Others

        13.2.2. Buccal Films 

        13.2.3. Liquid & Spray

            13.2.3.1. Aqueous Solutions

            13.2.3.2. Suspensions 

        13.2.4. Gels

        13.2.5. Others

    13.3. Market Value Forecast, by Route of Penetration, 2017–2031

        13.3.1. Sublingual Mucosa

        13.3.2. Buccal Mucosa

        13.3.3. Gingival Tissues

        13.3.4. Palatal Tissues

    13.4. Market Value Forecast, by Distribution Channel, 2017–2031

        13.4.1. Hospital Pharmacies

        13.4.2. Retail Pharmacies

        13.4.3. Online Pharmacies

    13.5. Market Value Forecast, by Indication, 2017–2031

        13.5.1. Cardiovascular Disorders

        13.5.2. Acute Pain Management

        13.5.3. Sedation

        13.5.4. Erectile Dysfunction

        13.5.5. Diabetes

        13.5.6. Others

    13.6. Market Value Forecast, by Country/Sub-region, 2017–2031

        13.6.1. Japan 

        13.6.2. China 

        13.6.3. India 

        13.6.4. Australia & New Zealand 

        13.6.5. South Korea

        13.6.6. Rest of Asia Pacific 

    13.7. Market Attractiveness Analysis 

        13.7.1. By Type 

        13.7.2. By Route of Penetration 

        13.7.3. By Distribution Channel 

        13.7.4. By Indication 

        13.7.5. By Country/Sub-region

14. Latin America Oral Transmucosal Drugs Market Analysis and Forecast

    14.1. Introduction

        14.1.1. Key Findings

    14.2. Market Value Forecast, by Type, 2017–2031

        14.2.1. Tablets

            14.2.1.1. Sublingual Tablets 

            14.2.1.2. Buccal Tablets 

            14.2.1.3. Lozenges & Troches

            14.2.1.4. Others

        14.2.2. Buccal Films 

        14.2.3. Liquid & Spray

            14.2.3.1. Aqueous Solutions

            14.2.3.2. Suspensions 

        14.2.4. Gels

        14.2.5. Others

    14.3. Market Value Forecast, by Route of Penetration, 2017–2031

        14.3.1. Sublingual Mucosa

        14.3.2. Buccal Mucosa

        14.3.3. Gingival Tissues

        14.3.4. Palatal Tissues

    14.4. Market Value Forecast, by Distribution Channel, 2017–2031

        14.4.1. Hospital Pharmacies

        14.4.2. Retail Pharmacies

        14.4.3. Online Pharmacies

    14.5. Market Value Forecast, by Indication, 2017–2031

        14.5.1. Cardiovascular Disorders

        14.5.2. Acute Pain Management

        14.5.3. Sedation

        14.5.4. Erectile Dysfunction

        14.5.5. Diabetes

        14.5.6. Others

    14.6. Market Value Forecast, by Country/Sub-region, 2017–2031

        14.6.1. Brazil 

        14.6.2. Mexico 

        14.6.3. Rest of Latin America 

    14.7. Market Attractiveness Analysis 

        14.7.1. By Type 

        14.7.2. By Route of Penetration 

        14.7.3. By Distribution Channel 

        14.7.4. By Indication 

        14.7.5. By Country/Sub-region

15. Middle East & Africa Oral Transmucosal Drugs Market Analysis and Forecast

    15.1. Introduction

        15.1.1. Key Findings

    15.2. Market Value Forecast, by Type, 2017–2031

        15.2.1. Tablets

            15.2.1.1. Sublingual Tablets 

            15.2.1.2. Buccal Tablets 

            15.2.1.3. Lozenges & Troches

            15.2.1.4. Others

        15.2.2. Buccal Films 

        15.2.3. Liquid & Spray

            15.2.3.1. Aqueous Solutions

            15.2.3.2. Suspensions 

        15.2.4. Gels

        15.2.5. Others

    15.3. Market Value Forecast, by Route of Penetration, 2017–2031

        15.3.1. Sublingual Mucosa

        15.3.2. Buccal Mucosa

        15.3.3. Gingival Tissues

        15.3.4. Palatal Tissues

    15.4. Market Value Forecast, by Distribution Channel, 2017–2031

        15.4.1. Hospital Pharmacies

        15.4.2. Retail Pharmacies

        15.4.3. Online Pharmacies

    15.5. Market Value Forecast, by Indication, 2017–2031

        15.5.1. Cardiovascular Disorders

        15.5.2. Acute Pain Management

        15.5.3. Sedation

        15.5.4. Erectile Dysfunction

        15.5.5. Diabetes

        15.5.6. Others

    15.6. Market Value Forecast, by Country/Sub-region, 2017–2031

        15.6.1. GCC Countries 

        15.6.2. South Africa 

        15.6.3. Rest of Middle East & Africa 

    15.7. Market Attractiveness Analysis 

        15.7.1. By Type 

        15.7.2. By Route of Penetration 

        15.7.3. By Distribution Channel 

        15.7.4. By Indication 

        15.7.5. By Country/Sub-region

16. Competition Landscape

    16.1. Market Share Analysis, by Company, 2020

    16.2. Company Profiles

        16.2.1. LTS Lohmann Therapie-Systeme AG

            16.2.1.1. Company Overview

            16.2.1.2. Company Financials

            16.2.1.3. Growth Strategies

            16.2.1.4. SWOT Analysis

        16.2.2. Soligenix

            16.2.2.1. Company Overview

            16.2.2.2. Company Financials16.

            16.2.2.3. Growth Strategies

            16.2.2.4. SWOT Analysis

        16.2.3. ZIM Laboratories Limited

            16.2.3.1. Company Overview

            16.2.3.2. Company Financials

            16.2.3.3. Growth Strategies

            16.2.3.4. SWOT Analysis

        16.2.4. Access Pharmaceutical, Inc.

            16.2.4.1. Company Overview

            16.2.4.2. Company Financials

            16.2.4.3. Growth Strategies

            16.2.4.4. SWOT Analysis 

        16.2.5. C.L Pharm

            16.2.5.1. Company Overview

            16.2.5.2. Company Financials

            16.2.5.3. Growth Strategies

            16.2.5.4. SWOT Analysis

        16.2.6. Seoul Pharmaceuticals

            16.2.6.1. Company Overview

            16.2.6.2. Company Financials

            16.2.6.3. Growth Strategies

            16.2.6.4. SWOT Analysis

        16.2.7. Cure Pharmaceutical

            16.2.7.1. Company Overview

            16.2.7.2. Company Financials

            16.2.7.3. Growth Strategies

            16.2.7.4. SWOT Analysis

        16.2.8. Aquestive Therapeutics, Inc.

            16.2.8.1. Company Overview

            16.2.8.2. Company Financials

            16.2.8.3. Growth Strategies

            16.2.8.4. SWOT Analysis

        16.2.9. Solvay S.A.

            16.2.9.1. Company Overview

            16.2.9.2. Company Financials

            16.2.9.3. Growth Strategies

            16.2.9.4. SWOT Analysis

        16.2.10. NAL Pharma

            16.2.10.1. Company Overview

            16.2.10.2. Company Financials

            16.2.10.3. Growth Strategies

            16.2.10.4. SWOT Analysis

        16.2.11. IntelGenx Corp.

            16.2.11.1. Company Overview

            16.2.11.2. Company Financials

            16.2.11.3. Growth Strategies

            16.2.11.4. SWOT Analysis

        16.2.12. Izun Pharmaceuticals

            16.2.12.1. Company Overview

            16.2.12.2. Company Financials

            16.2.12.3. Growth Strategies

            16.2.12.4. SWOT Analysis

        16.2.13. Eisai Co., Ltd

            16.2.13.1. Company Overview

            16.2.13.2. Company Financials

            16.2.13.3. Growth Strategies

            16.2.13.4. SWOT Analysis

        16.2.14. AstraZeneca

            16.2.14.1. Company Overview

            16.2.14.2. Company Financials

            16.2.14.3. Growth Strategies

            16.2.14.4. SWOT Analysis

        16.2.15. Otsuka Pharmaceutical Co., Ltd.

            16.2.15.1. Company Overview

            16.2.15.2. Company Financials

            16.2.15.3. Growth Strategies

            16.2.15.4. SWOT Analysis

        16.2.16. Pfizer, Inc.

            16.2.16.1. Company Overview

            16.2.16.2. Company Financials

            16.2.16.3. Growth Strategies

            16.2.16.4. SWOT Analysis

        16.2.17. Teva Pharmaceutical Industries Ltd.

            16.2.17.1. Company Overview

            16.2.17.2. Company Financials

            16.2.17.3. Growth Strategies

            16.2.17.4. SWOT Analysis

        16.2.18. GlaxoSmithKline plc

            16.2.18.1. Company Overview

            16.2.18.2. Company Financials

            16.2.18.3. Growth Strategies

            16.2.18.4. SWOT Analysis

        16.2.19. Mylan N.V.

            16.2.19.1. Company Overview

            16.2.19.2. Company Financials

            16.2.19.3. Growth Strategies

            16.2.19.4. SWOT Analysis

        16.2.20. Bristol-Myers Squibb Company

            16.2.20.1. Company Overview

            16.2.20.2. Company Financials

            16.2.20.3. Growth Strategies

            16.2.20.4. SWOT Analysis

List of Tables

Table 01: Global Oral Transmucosal Drugs Market Value (US$ Mn) Forecast, by Type, 2017–2031

Table 02: Global Oral Transmucosal Drugs Market Value (US$ Mn) Forecast, by Tablets, 2017–2031

Table 03: Global Oral Transmucosal Drugs Market Value (US$ Mn) Forecast, by Liquid & Spray, 2017–2031

Table 04: Global Oral Transmucosal Drugs Market Value (US$ Mn) Forecast, by Route of Penetration, 2017–2031

Table 05: Global Oral Transmucosal Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 06: Global Oral Transmucosal Drugs Market Value (US$ Mn) Forecast, by Indication, 2017–2031

Table 07: Global Oral Transmucosal Drugs Market Value (US$ Mn) Forecast, by Region, 2017–2031

Table 08: North America Oral Transmucosal Drugs Market Value (US$ Mn) Forecast, by Country, 2017–2031

Table 09: North America Oral Transmucosal Drugs Market Value (US$ Mn) Forecast, by Type, 2017–2031

Table 10: North America Oral Transmucosal Drugs Market Value (US$ Mn) Forecast, by Tablets, 2017–2031

Table 11: North America Oral Transmucosal Drugs Market Value (US$ Mn) Forecast, by Liquid & Spray, 2017–2031

Table 12: North America Oral Transmucosal Drugs Market Value (US$ Mn) Forecast, by Route of Penetration, 2017–2031

Table 13: North America Oral Transmucosal Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 14: North America Oral Transmucosal Drugs Market Value (US$ Mn) Forecast, by Indication, 2017–2031

Table 15: Europe Oral Transmucosal Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 16: Europe Oral Transmucosal Drugs Market Value (US$ Mn) Forecast, by Type, 2017–2031

Table 17: Europe Oral Transmucosal Drugs Market Value (US$ Mn) Forecast, by Tablets, 2017–2031

Table 18: Europe Oral Transmucosal Drugs Market Value (US$ Mn) Forecast, by Liquid & Spray, 2017–2031

Table 19: Europe Oral Transmucosal Drugs Market Value (US$ Mn) Forecast, by Route of Penetration, 2017–2031

Table 20: Europe Oral Transmucosal Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 21: Europe Oral Transmucosal Drugs Market Value (US$ Mn) Forecast, by Indication, 2017–2031

Table 22: Asia Pacific Oral Transmucosal Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 23: Asia Pacific Oral Transmucosal Drugs Market Value (US$ Mn) Forecast, by Type, 2017–2031

Table 24: Asia Pacific Oral Transmucosal Drugs Market Value (US$ Mn) Forecast, by Tablets, 2017–2031

Table 25: Asia Pacific Oral Transmucosal Drugs Market Value (US$ Mn) Forecast, by Liquid & Spray, 2017–2031

Table 26: Asia Pacific Oral Transmucosal Drugs Market Value (US$ Mn) Forecast, by Route of Penetration, 2017–2031

Table 27: Asia Pacific Oral Transmucosal Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 28: Asia Pacific Oral Transmucosal Drugs Market Value (US$ Mn) Forecast, by Indication, 2017–2031

Table 29: Latin America Oral Transmucosal Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 30: Latin America Oral Transmucosal Drugs Market Value (US$ Mn) Forecast, by Type, 2017–2031

Table 31: Latin America Oral Transmucosal Drugs Market Value (US$ Mn) Forecast, by Tablets, 2017–2031

Table 32: Latin America Oral Transmucosal Drugs Market Value (US$ Mn) Forecast, by Liquid & Spray, 2017–2031

Table 33: Latin America Oral Transmucosal Drugs Market Value (US$ Mn) Forecast, by Route of Penetration, 2017–2031

Table 34: Latin America Oral Transmucosal Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 35: Latin America Oral Transmucosal Drugs Market Value (US$ Mn) Forecast, by Indication, 2017–2031

Table 36: Middle East & Africa Oral Transmucosal Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 37: Middle East & Africa Oral Transmucosal Drugs Market Value (US$ Mn) Forecast, by Type, 2017–2031

Table 38: Middle East & Africa Oral Transmucosal Drugs Market Value (US$ Mn) Forecast, by Tablets, 2017–2031

Table 39: Middle East & Africa Oral Transmucosal Drugs Market Value (US$ Mn) Forecast, by Liquid & Spray, 2017–2031

Table 40: Middle East & Africa Oral Transmucosal Drugs Market Value (US$ Mn) Forecast, by Route of Penetration, 2017–2031

Table 41: Middle East & Africa Oral Transmucosal Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 42: Middle East & Africa Oral Transmucosal Drugs Market Value (US$ Mn) Forecast, by Indication, 2017–2031

List of Figures

Figure 01: Global Oral Transmucosal Drugs Market Value (US$ Mn) Forecast, 2017–2031

Figure 02: Global Oral Transmucosal Drugs Market Value Share Analysis, by Type, 2020 and 2031

Figure 03: Global Oral Transmucosal Drugs Market Attractiveness Analysis, by Type, 2021–2031

Figure 04: Global Oral Transmucosal Drugs Market Value (US$ Mn), by Tablets, 2017?2031

Figure 05: Global Oral Transmucosal Drugs Market Value (US$ Mn), by Buccal Films, 2017?2031

Figure 06: Global Oral Transmucosal Drugs Market Value (US$ Mn), by Liquid & Spray, 2017?2031

Figure 07: Global Oral Transmucosal Drugs Market Value (US$ Mn), by Gels, 2017?2031

Figure 08: Global Oral Transmucosal Drugs Market Value (US$ Mn), by Others, 2017?2031

Figure 09: Global Oral Transmucosal Drugs Market Value Share Analysis, by Route of Penetration, 2020 and 2031

Figure 10: Global Oral Transmucosal Drugs Market Attractiveness Analysis, by Route of Penetration, 2021–2031

Figure 11: Global Oral Transmucosal Drugs Market Value (US$ Mn), by Sublingual Mucosa, 2017–2031

Figure 12: Global Oral Transmucosal Drugs Market Value (US$ Mn), by Buccal Mucosa, 2017–2031

Figure 13: Global Oral Transmucosal Drugs Market Value (US$ Mn), by Gingival Tissues, 2017–2031

Figure 14: Global Oral Transmucosal Drugs Market Value (US$ Mn), by Palatal Tissues, 2017–2031

Figure 15: Global Oral Transmucosal Drugs Market Value Share Analysis, by Distribution Channel, 2020 and 2031

Figure 16: Global Oral Transmucosal Drugs Market Attractiveness Analysis, by Distribution Channel, 2021–2031

Figure 17: Global Oral Transmucosal Drugs Market Value (US$ Mn), by Hospital Pharmacies, 2017?2031

Figure 18: Global Oral Transmucosal Drugs Market Value (US$ Mn), by Retail Pharmacies, 2017?2031

Figure 19: Global Oral Transmucosal Drugs Market Value (US$ Mn), by Online Pharmacies, 2017?2031

Figure 20: Global Oral Transmucosal Drugs Market Value Share Analysis, by Indication, 2020 and 2031

Figure 21: Global Oral Transmucosal Drugs Market Attractiveness Analysis, by Indication, 2021–2031

Figure 22: Global Oral Transmucosal Drugs Market Value (US$ Mn), Cardiovascular Disorders, 2017–2031

Figure 23: Global Oral Transmucosal Drugs Market Value (US$ Mn), by Acute Pain Management, 2017–2031

Figure 24: Global Oral Transmucosal Drugs Market Value (US$ Mn), by Sedation, 2017–2031

Figure 25: Global Oral Transmucosal Drugs Market Value (US$ Mn), by Erectile Dysfunction, 2017–2031

Figure 26: Global Oral Transmucosal Drugs Market Value (US$ Mn), by Diabetes, 2017–2031

Figure 27: Global Oral Transmucosal Drugs Market Value (US$ Mn), by Others, 2017–2031

Figure 28: Global Oral Transmucosal Drugs Market Value Share Analysis, by Region, 2020 and 2031

Figure 29: Global Oral Transmucosal Drugs Market Attractiveness Analysis, by Region, 2021–2031

Figure 30: North America Oral Transmucosal Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031

Figure 31: North America Oral Transmucosal Drugs Market Value Share, by Country, 2020 and 2031

Figure 32: North America Oral Transmucosal Drugs Market Attractiveness Analysis, by Country, 2021–2031

Figure 33: North America Oral Transmucosal Drugs Market Value Share Analysis, by Type, 2020 and 2031

Figure 34: North America Oral Transmucosal Drugs Market Attractiveness Analysis, by Type, 2021–2031

Figure 35: North America Oral Transmucosal Drugs Market Value Share Analysis, by Route of Penetration, 2020 and 2031

Figure 36: North America Oral Transmucosal Drugs Market Attractiveness Analysis, by Route of Penetration, 2021–2031

Figure 37: North America Oral Transmucosal Drugs Market Value Share Analysis, by Distribution Channel, 2020 and 2031

Figure 38: North America Oral Transmucosal Drugs Market Attractiveness Analysis, by Distribution Channel, 2021–2031

Figure 39: North America Oral Transmucosal Drugs Market Value Share Analysis, by Indication, 2020 and 2031

Figure 40: North America Oral Transmucosal Drugs Market Attractiveness Analysis, by Indication, 2021–2031

Figure 41: Europe Oral Transmucosal Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031

Figure 42: Europe Oral Transmucosal Drugs Market Value Share, by Country/Sub-region, 2020 and 2031

Figure 43: Europe Oral Transmucosal Drugs Market Attractiveness Analysis, by Country/Sub-region, 2021–2031

Figure 44: Europe Oral Transmucosal Drugs Market Value Share Analysis, by Type, 2020 and 2031

Figure 45: Europe Oral Transmucosal Drugs Market Attractiveness Analysis, by Type, 2021–2031

Figure 46: Europe Oral Transmucosal Drugs Market Value Share Analysis, by Route of Penetration, 2020 and 2031

Figure 47: Europe Oral Transmucosal Drugs Market Attractiveness Analysis, by Route of Penetration, 2021–2031

Figure 48: Europe Oral Transmucosal Drugs Market Value Share Analysis, by Distribution Channel, 2020 and 2031

Figure 49: Europe Oral Transmucosal Drugs Market Attractiveness Analysis, by Distribution Channel, 2021–2031

Figure 50: Europe Oral Transmucosal Drugs Market Value Share Analysis, by Indication, 2020 and 2031

Figure 51: Europe Oral Transmucosal Drugs Market Attractiveness Analysis, by Indication, 2021–2031

Figure 52: Asia Pacific Oral Transmucosal Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031

Figure 53: Asia Pacific Oral Transmucosal Drugs Market Value Share, by Country/Sub-region, 2020 and 2031

Figure 54: Asia Pacific Oral Transmucosal Drugs Market Attractiveness Analysis, by Country/Sub-region, 2021–2031

Figure 55: Asia Pacific Oral Transmucosal Drugs Market Value Share Analysis, by Type, 2020 and 2031

Figure 56: Asia Pacific Oral Transmucosal Drugs Market Attractiveness Analysis, by Type, 2021–2031

Figure 57: Asia Pacific Oral Transmucosal Drugs Market Value Share Analysis, by Route of Penetration, 2020 and 2031

Figure 58: Asia Pacific Oral Transmucosal Drugs Market Attractiveness Analysis, by Route of Penetration, 2021–2031

Figure 59: Asia Pacific Oral Transmucosal Drugs Market Value Share Analysis, by Distribution Channel, 2020 and 2031

Figure 60: Asia Pacific Oral Transmucosal Drugs Market Attractiveness Analysis, by Distribution Channel, 2021–2031

Figure 61: Asia Pacific Oral Transmucosal Drugs Market Value Share Analysis, by Indication, 2020 and 2031

Figure 62: Asia Pacific Oral Transmucosal Drugs Market Attractiveness Analysis, by Indication, 2021–2031

Figure 63: Latin America Oral Transmucosal Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031

Figure 64: Latin America Oral Transmucosal Drugs Market Value Share, by Country/Sub-region, 2020 and 2031

Figure 65: Latin America Oral Transmucosal Drugs Market Attractiveness Analysis, by Country/Sub-region, 2021–2031

Figure 66: Latin America Oral Transmucosal Drugs Market Value Share Analysis, by Type, 2020 and 2031

Figure 67: Latin America Oral Transmucosal Drugs Market Attractiveness Analysis, by Type, 2021–2031

Figure 68: Latin America Oral Transmucosal Drugs Market Value Share Analysis, by Route of Penetration, 2020 and 2031

Figure 69: Latin America Oral Transmucosal Drugs Market Attractiveness Analysis, by Route of Penetration, 2021–2031

Figure 70: Latin America Oral Transmucosal Drugs Market Value Share Analysis, by Distribution Channel, 2020 and 2031

Figure 71: Latin America Oral Transmucosal Drugs Market Attractiveness Analysis, by Distribution Channel, 2021–2031

Figure 72: Latin America Oral Transmucosal Drugs Market Value Share Analysis, by Indication, 2020 and 2031

Figure 73: Latin America Oral Transmucosal Drugs Market Attractiveness Analysis, by Indication, 2021–2031

Figure 74: Middle East & Africa Oral Transmucosal Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031

Figure 75: Middle East & Africa Oral Transmucosal Drugs Market Value Share, by Country/Sub-region, 2020 and 2031

Figure 76: Middle East & Africa Oral Transmucosal Drugs Market Attractiveness Analysis, by Country/Sub-region, 2021–2031

Figure 77: Middle East & Africa Oral Transmucosal Drugs Market Value Share Analysis, by Type, 2020 and 2031

Figure 78: Middle East & Africa Oral Transmucosal Drugs Market Attractiveness Analysis, by Type, 2021–2031

Figure 79: Middle East & Africa Oral Transmucosal Drugs Market Value Share Analysis, by Route of Penetration, 2020 and 2031

Figure 80: Middle East & Africa Oral Transmucosal Drugs Market Attractiveness Analysis, by Route of Penetration, 2021–2031

Figure 81: Middle East & Africa Oral Transmucosal Drugs Market Value Share Analysis, by Distribution Channel, 2020 and 2031

Figure 82: Middle East & Africa Oral Transmucosal Drugs Market Attractiveness Analysis, by Distribution Channel, 2021–2031

Figure 83: Middle East & Africa Oral Transmucosal Drugs Market Value Share Analysis, by Indication, 2020 and 2031

Figure 84: Middle East & Africa Oral Transmucosal Drugs Market Attractiveness Analysis, by Indication, 2021–2031

Figure 85: Position Analysis, 2020, by Tier and Size of the Company

Custom Market Research Services

TMR offers custom market research services that help clients to get information on their business scenario required where syndicated solutions are not enough.

Request Customization

Oral Transmucosal Drugs Market